Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth-Ayerst Protonix I.V.

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The intravenous proton pump inhibitor pantoprazole will be launched in mid-April, according to the firm. Approved March 22, Protonix I.V. is indicated for "short-term treatment (seven to 10 days) of gastroesophageal reflux disease, as an alternative to oral therapy in patients who are unable to continue taking" oral Protonix. The tablet version of Protonix was launched in May last yea
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel